Nvidia has teamed up with pharmaceutical heavyweight Eli Lilly to plow as much as $1 billion right into a analysis lab over the subsequent 5 years to advance the event of basis fashions for AI-assisted drug discovery.
Introduced on the JPMorgan Healthcare convention on Monday, the collaboration will span the infrastructure, expertise, and compute essential to develop these biology and chemistry fashions utilizing Nvidia’s BioNeMo software program platform and Vera Rubin accelerators.
Launched in fall 2022, simply months earlier than ChatGPT kicked off the AI arms race, BioNeMo is an open supply framework for constructing and coaching deep studying fashions to be used in drug discovery.
Situated within the San Francisco Bay Space, the so-called co-innovation lab will carry collectively Eli Lilly’s high biologists and chemists to work alongside Nvidia’s software program engineers and mannequin devs, when it opens later this yr.
“Combining our volumes of information and scientific information with Nvidia’s computational energy and model-building experience might reinvent drug discovery as we all know it,” Eli Lilly CEO David Ricks mentioned in a canned assertion.
“The main target can be on making a laboratory the place AI software program (the dry lab) and robotic {hardware} (the moist lab) speak to one another 24/7, conserving people within the loop with out the necessity for fixed reprogramming the robotic or manually finishing each step of the experiments.. This amplifies the scientist’s productiveness, elevating them to a strategic lead, whereas the system executes the iterative testing cycle at machine pace,” an Nvidia spokes individual advised El Reg.
From there, the 2 firms will harness Nvidia’s newly unveiled Vera Rubin compute platform. Introduced at CES final week, the system guarantees a fivefold enhance in efficiency over Nvidia’s prior-gen Blackwell GPUs. These chips will present the computational grunt obligatory to coach new basis fashions primarily based on the lab’s analysis.
This means the lab can be among the many first to get its arms on the chips, which are not anticipated to be obtainable in any important numbers till the second half of this yr.
Within the meantime, it is not like Eli Lilly is hurting for compute. At GTC DC final October, the pharmaceutical large revealed it had deployed a Blackwell Extremely-based SuperPOD full with 1,016 B300 GPUs to assist its exploration into computational biology and chemistry.
The lab’s sole focus will not be restricted to AI drug discovery, nevertheless. Researchers may even discover purposes for AI in scientific growth, manufacturing, and industrial operations.
For instance, Eli Lilly can also be investigating Nvidia’s Omniverse Robotics platforms as a method to optimize its manufacturing vegetation and enhance manufacturing of high-demand medication. ®
Up to date at 2038 to incorporate a quote from Nvidia.
Nvidia has teamed up with pharmaceutical heavyweight Eli Lilly to plow as much as $1 billion right into a analysis lab over the subsequent 5 years to advance the event of basis fashions for AI-assisted drug discovery.
Introduced on the JPMorgan Healthcare convention on Monday, the collaboration will span the infrastructure, expertise, and compute essential to develop these biology and chemistry fashions utilizing Nvidia’s BioNeMo software program platform and Vera Rubin accelerators.
Launched in fall 2022, simply months earlier than ChatGPT kicked off the AI arms race, BioNeMo is an open supply framework for constructing and coaching deep studying fashions to be used in drug discovery.
Situated within the San Francisco Bay Space, the so-called co-innovation lab will carry collectively Eli Lilly’s high biologists and chemists to work alongside Nvidia’s software program engineers and mannequin devs, when it opens later this yr.
“Combining our volumes of information and scientific information with Nvidia’s computational energy and model-building experience might reinvent drug discovery as we all know it,” Eli Lilly CEO David Ricks mentioned in a canned assertion.
“The main target can be on making a laboratory the place AI software program (the dry lab) and robotic {hardware} (the moist lab) speak to one another 24/7, conserving people within the loop with out the necessity for fixed reprogramming the robotic or manually finishing each step of the experiments.. This amplifies the scientist’s productiveness, elevating them to a strategic lead, whereas the system executes the iterative testing cycle at machine pace,” an Nvidia spokes individual advised El Reg.
From there, the 2 firms will harness Nvidia’s newly unveiled Vera Rubin compute platform. Introduced at CES final week, the system guarantees a fivefold enhance in efficiency over Nvidia’s prior-gen Blackwell GPUs. These chips will present the computational grunt obligatory to coach new basis fashions primarily based on the lab’s analysis.
This means the lab can be among the many first to get its arms on the chips, which are not anticipated to be obtainable in any important numbers till the second half of this yr.
Within the meantime, it is not like Eli Lilly is hurting for compute. At GTC DC final October, the pharmaceutical large revealed it had deployed a Blackwell Extremely-based SuperPOD full with 1,016 B300 GPUs to assist its exploration into computational biology and chemistry.
The lab’s sole focus will not be restricted to AI drug discovery, nevertheless. Researchers may even discover purposes for AI in scientific growth, manufacturing, and industrial operations.
For instance, Eli Lilly can also be investigating Nvidia’s Omniverse Robotics platforms as a method to optimize its manufacturing vegetation and enhance manufacturing of high-demand medication. ®
Up to date at 2038 to incorporate a quote from Nvidia.
